Tris Pharma has received additional ex-US approvals for its attention deficit hyperactivity disorder (ADHD) treatments, ...

Veeva’s VP of global medical, Christoph Bug, emphasises the importance of scientific exchange between clinical experts and ...

Diagnosed prevalent cases of Parkinson’s disease will grow at 1.94% annually in the seven major markets between 2023 and 2033 ...

UK Health Secretary Wes Streeting outlaid the key shifts needed to fix a “fragmented” NHS at the Jefferies London Healthcare ...

Pharmanovia has signed a licensing agreement with Lindis Biotech to commercialise catumaxomab for malignant ascites.

The UK’s NICE has rejected a deal for the reimbursement of Daiichi Sankyo and AstraZeneca's breast cancer drug Enhertu for ...

The Phase III BROOKLYN trial saw HeFH patients randomly assigned in a 2:1 ratio to receive either obicetrapib or a placebo ...

The US FDA has issued a CRL for sNDA of Astellas Pharma’s IZERVAY, a treatment for geographic atrophy (GA) secondary to AMD.

The FDA has released a draft of new guidance addressing common FAQs about the development of potential CGT treatments.

Novo Nordisk Pharmatech has entered an agreement with Signet Chemical Corporation for the distribution of its pharmaceutical range of ...

Aclaris Therapeutics has secured an exclusive license from Biosion for the global rights to two new antibodies.

The upcoming clinical trial conferences will host talks on supply chain resilience, AI’s growing role and forging industry ...